Here are five takeaways from the agreed acquisition:
1. Misonix said it will issue around 5.7 million new shares to Solys unitholders and will assume the company’s outstanding secured debt of approximately $20 million.
2. The boards of both companies have approved the deal, which is slated for completion in the third quarter of 2019.
3. When the deal closes, Misonix shareholders will own 64 percent of the combined entity and Solys unitholders will own 36 percent.
4. Solys’ advanced wound care product, TheraSkin — a cellular- and tissue-based product for regenerative wound healing — is designed to treat chronic wounds which are difficult to heal.
5. Solys is expected to reach sales of roughly $32 million for 2019 with the pro forma firm is expected to generate over $80 million in sales. The combined company expects revenue growth of over 20 percent over the next couple of years.
More articles on biologics:
UNC, NC State scientists collaborate to print human body tissues
Expesicor, Novoron Bioscience to collaborate on treatment for central nervous system disorders
4 benefits of stem cells in orthopedics from Dr. Jeffrey Carroll
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
